Iyona Rajkomar
Directeur/Membre du Conseil chez Abcuro, Inc.
Profil
Iyona Rajkomar currently works at Abcuro, Inc., as Director from 2021, Antios Therapeutics, Inc., as Director, ADCendo ApS, as Director from 2024, and Dawn Biopharma, as Managing Partner.
Ms. Rajkomar also formerly worked at Horama SA, as Director, Amolyt Pharma SAS, as Director, Advent Venture Partners LLP, as Principal from 2015 to 2019, Bryan, Garnier & Co Ltd., as Research Analyst from 2009 to 2010, UBS Ltd.
(Broker), as Associate Research Analyst, and Pontifax Management Co. Ltd., as Partner from 2019 to 2023.
Ms. Rajkomar received her graduate degree from the University of London.
Postes actifs de Iyona Rajkomar
| Sociétés | Poste | Début |
|---|---|---|
Abcuro, Inc.
 Abcuro, Inc. Miscellaneous Commercial ServicesCommercial Services Abcuro, Inc. develops bio-therapeutics for the treatment of autoimmunity and cancer. the company was founded in 2015 and is headquartered in Newton, MA. | Directeur/Membre du Conseil | 07/01/2021 |
Antios Therapeutics, Inc.
 Antios Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Antios Therapeutics, Inc. operates as a biopharmaceutical company devoted to developing therapies for viral diseases. The company was founded by Abel De La Rosa, Doug Mayers and Idean Marvasty on October 30, 2018 and is headquartered in Atlanta, GA. | Directeur/Membre du Conseil | - |
ADCendo ApS
 ADCendo ApS BiotechnologyHealth Technology ADCendo ApS is a Danish company that is focused on developing antibody-drug conjugates (ADCs) to treat underserved cancers. The company is based in Humlebaek, Denmark. The company completed a series A extension financing round in 2023, which brought its funds to 82 million EUR to advance into clinical development. The investors in the company include Novo Holdings, Ysios Capital, Pontifax Venture Capital, RA Capital Management, HealthCap, and Gilde Healthcare. The company was founded in 2017 by Christoffer Nielsen, Henrik Stage. Michael Pehl has been the CEO of the company since 2021. | Directeur/Membre du Conseil | 29/05/2024 |
Anciens postes connus de Iyona Rajkomar
| Sociétés | Poste | Fin |
|---|---|---|
Pontifax Management Co. Ltd.
 Pontifax Management Co. Ltd. Investment ManagersFinance Pontifax Management Co. Ltd. (Pontifax) is a venture capital firm founded in 2004 by Eliyahu Hurvitz. The firm is headquartered in Herzliya Pituach, Israel. | Private Equity Investor | 05/01/2023 |
Advent Venture Partners LLP
 Advent Venture Partners LLP Investment ManagersFinance Advent Venture Partners LLP (AVP) is a private equity/venture capital firm founded in 1981 by David James Scott Cooksey. The firm is headquartered in London, United Kingdom. | Analyste en capital-investissement | 01/02/2019 |
Bryan, Garnier & Co Ltd.
 Bryan, Garnier & Co Ltd. Investment Banks/BrokersFinance Bryan, Garnier & Co Ltd. is a European, full-service growth-focused independent investment bank for technology, healthcare, consumer, and business services companies. The private company is based in London, UK, and has a global presence of subsidiaries in several regions. The British company is well-positioned in a capex intensive industry that is increasingly dynamic both in capital raising and M & A, driven by the 4th Industrial Revolution. Bryan Garnier is the world's leading independent full-service investment bank for European healthcare and technology-led companies and their investors. The company is focused on new disruptive technologies and alternative production models in a variety of domains geared towards fighting climate change and environmental degradation. The consumer sector is transformed across its segments by the way digital natives relate to brands, products, and the environment. The company was founded in 1996 by Olivier Marie Paul Garnier de Falletans. | Analyst-Equity | 01/10/2010 |
UBS Ltd. (Broker)
 UBS Ltd. (Broker) Investment Banks/BrokersFinance UBS Ltd. (Broker) is the Great Britain-based brokerage division of UBS Ltd.,the wholly-owned subsidiary of Switzerland-based UBS AG (SWX: UBSN; NYSE: UBS). Established in 1975, the firm is located in London. UBS Ltd.'s business is organized in three departments: fixed-income, rates and currencies; equity and investment banking. UBS Ltd. (Broker) engages in equity trading, equity derivatives and equity-linked products. The equity research department covers a diverse range of sectors globally and also supplies macroeconomic analysis, quantitative and derivative research. The fixed-income, rates and currency business covers credit, rates, commodities including energy and metals, municipal bonds, Forex and cash and collateral trading globally. Their investment banking activities include analysis, structuring, transaction negotiation and communication. | Analyst-Equity | 27/04/2009 |
Horama SA
 Horama SA BiotechnologyHealth Technology Horama SA engages in the development of gene therapies, It focuses on ophthalmological diseases for preserving visual autonomy of patients. The company was founded by Denis Cayet, Christian Hamel, Guylene Le Meur, Philippe Moullier, Vasiliki Kalatzis, and Michel Weberin March 2014 and is headquartered in Paris, France. | Directeur/Membre du Conseil | - |
Formation de Iyona Rajkomar
| University of London | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 9 |
|---|---|
UBS Ltd. (Broker)
UBS Ltd. (Broker) Investment Banks/BrokersFinance UBS Ltd. (Broker) is the Great Britain-based brokerage division of UBS Ltd.,the wholly-owned subsidiary of Switzerland-based UBS AG (SWX: UBSN; NYSE: UBS). Established in 1975, the firm is located in London. UBS Ltd.'s business is organized in three departments: fixed-income, rates and currencies; equity and investment banking. UBS Ltd. (Broker) engages in equity trading, equity derivatives and equity-linked products. The equity research department covers a diverse range of sectors globally and also supplies macroeconomic analysis, quantitative and derivative research. The fixed-income, rates and currency business covers credit, rates, commodities including energy and metals, municipal bonds, Forex and cash and collateral trading globally. Their investment banking activities include analysis, structuring, transaction negotiation and communication. | Finance |
Bryan, Garnier & Co Ltd.
Bryan, Garnier & Co Ltd. Investment Banks/BrokersFinance Bryan, Garnier & Co Ltd. is a European, full-service growth-focused independent investment bank for technology, healthcare, consumer, and business services companies. The private company is based in London, UK, and has a global presence of subsidiaries in several regions. The British company is well-positioned in a capex intensive industry that is increasingly dynamic both in capital raising and M & A, driven by the 4th Industrial Revolution. Bryan Garnier is the world's leading independent full-service investment bank for European healthcare and technology-led companies and their investors. The company is focused on new disruptive technologies and alternative production models in a variety of domains geared towards fighting climate change and environmental degradation. The consumer sector is transformed across its segments by the way digital natives relate to brands, products, and the environment. The company was founded in 1996 by Olivier Marie Paul Garnier de Falletans. | Finance |
Advent Venture Partners LLP
Advent Venture Partners LLP Investment ManagersFinance Advent Venture Partners LLP (AVP) is a private equity/venture capital firm founded in 1981 by David James Scott Cooksey. The firm is headquartered in London, United Kingdom. | Finance |
Pontifax Management Co. Ltd.
Pontifax Management Co. Ltd. Investment ManagersFinance Pontifax Management Co. Ltd. (Pontifax) is a venture capital firm founded in 2004 by Eliyahu Hurvitz. The firm is headquartered in Herzliya Pituach, Israel. | Finance |
Amolyt Pharma SAS
 Amolyt Pharma SAS Pharmaceuticals: MajorHealth Technology Amolyt Pharma SAS engages in development of biopharmaceutical drugs, proteins and peptides for the treatment of metabolic diseases. The company was founded by Thierry Abribat in 2014 and is headquartered in Ecully, France. | Health Technology |
Horama SA
Horama SA BiotechnologyHealth Technology Horama SA engages in the development of gene therapies, It focuses on ophthalmological diseases for preserving visual autonomy of patients. The company was founded by Denis Cayet, Christian Hamel, Guylene Le Meur, Philippe Moullier, Vasiliki Kalatzis, and Michel Weberin March 2014 and is headquartered in Paris, France. | Health Technology |
Abcuro, Inc.
Abcuro, Inc. Miscellaneous Commercial ServicesCommercial Services Abcuro, Inc. develops bio-therapeutics for the treatment of autoimmunity and cancer. the company was founded in 2015 and is headquartered in Newton, MA. | Commercial Services |
Antios Therapeutics, Inc.
Antios Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Antios Therapeutics, Inc. operates as a biopharmaceutical company devoted to developing therapies for viral diseases. The company was founded by Abel De La Rosa, Doug Mayers and Idean Marvasty on October 30, 2018 and is headquartered in Atlanta, GA. | Health Technology |
ADCendo ApS
ADCendo ApS BiotechnologyHealth Technology ADCendo ApS is a Danish company that is focused on developing antibody-drug conjugates (ADCs) to treat underserved cancers. The company is based in Humlebaek, Denmark. The company completed a series A extension financing round in 2023, which brought its funds to 82 million EUR to advance into clinical development. The investors in the company include Novo Holdings, Ysios Capital, Pontifax Venture Capital, RA Capital Management, HealthCap, and Gilde Healthcare. The company was founded in 2017 by Christoffer Nielsen, Henrik Stage. Michael Pehl has been the CEO of the company since 2021. | Health Technology |